Atwood & Palmer’s Neurocrine Biosciences NBIX Stock Holding History

Atwood & Palmer’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$710	Hold	5	–	–	﹤0.01%	470
2026 Q2	$843	Hold	5	–	–	﹤0.01%	460
2026 Q1	$659	Hold	5	–	–	﹤0.01%	494
2025 Q4	$710	Hold	5	–	–	﹤0.01%	469
2025 Q3	$702	Hold	5	–	–	﹤0.01%	467
2025 Q2	$629	Hold	5	–	–	﹤0.01%	492
2025 Q1	$553	Hold	5	–	–	﹤0.01%	422
2024 Q4	$683	Hold	5	–	–	﹤0.01%	448
2024 Q3	$577	Hold	5	–	–	﹤0.01%	448
2024 Q2	$689	Hold	5	–	–	﹤0.01%	421
2024 Q1	$690	Hold	5	–	–	﹤0.01%	399
2023 Q4	$659	Hold	5	–	–	﹤0.01%	384
2023 Q3	$563	Hold	5	–	–	﹤0.01%	382
2023 Q2	$472	Hold	5	–	–	﹤0.01%	384
2023 Q1	$507	Buy	+5	New	+$520	﹤0.01%	358

Other funds holding NBIX

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return

RSC

Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return

MNBTD

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

PCS

Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return

CCAL

City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

Atwood & Palmer's NBIX Position: Q3 2026 in Review

Atwood & Palmer held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 5 shares worth $710. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Atwood & Palmer first reported a position in NBIX in Q1 2023 and has held it in 15 quarters since. The position peaked at $843 in Q2 2026. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Atwood & Palmer held 5 shares of Neurocrine Biosciences worth $710 as of Q3 2026.
Atwood & Palmer left its Neurocrine Biosciences share count unchanged in Q3 2026.
Neurocrine Biosciences made up ﹤0.01% of Atwood & Palmer's portfolio in Q3 2026, its #470 holding.
Atwood & Palmer first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 15 quarters since.
Atwood & Palmer's Neurocrine Biosciences position peaked at $843 in Q2 2026.
21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Atwood & Palmer's 13F filing for Q3 2026, filed 8 Oct 2026.